1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
2
|
Cancer Genome Atlas Research Network.
Comprehensive genomic characterization of squamous cell lung
cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Imielinski M, Berger AH, Hammerman PS, et
al: Mapping the hallmarks of lung adenocarcinoma with massively
parallel sequencing. Cell. 150:1107–1120. 2012. View Article : Google Scholar : PubMed/NCBI
|
4
|
Wistuba II, Gazdar AF and Minna JD:
Molecular genetics of small cell lung carcinoma. Semin Oncol.
28:3–13. 2001. View Article : Google Scholar : PubMed/NCBI
|
5
|
Peifer M, Fernandez-Cuesta L, Sos ML, et
al: Integrative genome analyses identify key somatic driver
mutations of small-cell lung cancer. Nat Genet. 44:1104–1110. 2012.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Weir BA, Woo MS, Getz G, et al:
Characterizing the cancer genome in lung adenocarcinoma. Nature.
450:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
|
7
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
8
|
Yasuda H, Kobayashi S and Costa DB: EGFR
exon 20 insertion mutations in non-small-cell lung cancer:
preclinical data and clinical implications. Lancet Oncol.
13:e23–31. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Yasuda H, Park E, Yun CH, et al:
Structural, biochemical, and clinical characterization of epidermal
growth factor receptor (EGFR) exon 20 insertion mutations in lung
cancer. Sci Transl Med. 5:216ra1772013. View Article : Google Scholar : PubMed/NCBI
|
10
|
Soda M, Choi YL, Enomoto M, et al:
Identification of the transforming EML4-ALK fusion gene in
non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
11
|
Choi YL, Takeuchi K, Soda M, et al:
Identification of novel isoforms of the EML4-ALK transforming gene
in non-small cell lung cancer. Cancer Res. 68:4971–4976. 2008.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Weiss J, Sos ML, Seidel D, et al: Frequent
and focal FGFR1 amplification associates with therapeutically
tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl
Med. 2:62ra932010. View Article : Google Scholar : PubMed/NCBI
|
13
|
Costa DB, Halmos B, Kumar A, et al: BIM
mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung
cancers with oncogenic EGFR mutations. PLoS Med. 4:1669–1680. 2007.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Yasuda H, de Figueiredo-Pontes LL,
Kobayashi S and Costa DB: Preclinical rationale for use of the
clinically available multitargeted tyrosine kinase inhibitor
crizotinib in ROS1-translocated lung cancer. J Thorac Oncol.
7:1086–1090. 2012. View Article : Google Scholar
|
15
|
Liao RG, Jung J, Tchaicha J, et al:
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell
carcinoma. Cancer Res. 73:5195–5205. 2013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Dutt A, Ramos AH, Hammerman PS, et al:
Inhibitor-sensitive FGFR1 amplification in human non-small cell
lung cancer. PLoS One. 6:e203512011. View Article : Google Scholar : PubMed/NCBI
|
17
|
Pardo OE, Latigo J, Jeffery RE, et al: The
fibroblast growth factor receptor inhibitor PD173074 blocks small
cell lung cancer growth in vitro and in vivo. Cancer Res.
69:8645–8651. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Dieci MV, Arnedos M, Andre F and Soria JC:
Fibroblast growth factor receptor inhibitors as a cancer treatment:
from a biologic rationale to medical perspectives. Cancer Discov.
3:264–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
19
|
Turner N and Grose R: Fibroblast growth
factor signalling: from development to cancer. Nat Rev Cancer.
10:116–129. 2010. View
Article : Google Scholar : PubMed/NCBI
|
20
|
Donnem T, Al-Shibli K, Al-Saad S, Busund
LT and Bremnes RM: Prognostic impact of fibroblast growth factor 2
in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B
predicts poor survival. J Thorac Oncol. 4:578–585. 2009. View Article : Google Scholar : PubMed/NCBI
|
21
|
Rades D, Seibold ND, Gebhard MP, Noack F,
Bruchhage KL and Schild SE: Fibroblast growth factor 2 is of
prognostic value for patients with locally advanced squamous cell
carcinoma of the head and neck. Strahlenther Onkol. 190:68–74.
2014. View Article : Google Scholar : PubMed/NCBI
|
22
|
Wilson TR, Fridlyand J, Yan Y, et al:
Widespread potential for growth-factor-driven resistance to
anticancer kinase inhibitors. Nature. 487:505–509. 2012. View Article : Google Scholar : PubMed/NCBI
|
23
|
Nomura S, Yoshitomi H, Takano S, et al:
FGF10/FGFR2 signal induces cell migration and invasion in
pancreatic cancer. Br J Cancer. 99:305–313. 2008. View Article : Google Scholar : PubMed/NCBI
|
24
|
Ohgino K, Soejima K, Yasuda H, et al:
Expression of fibroblast growth factor 9 is associated with poor
prognosis in patients with resected non-small cell lung cancer.
Lung Cancer. 83:90–96. 2014. View Article : Google Scholar : PubMed/NCBI
|
25
|
Yin Y, Betsuyaku T, Garbow JR, Miao J,
Govindan R and Ornitz DM: Rapid induction of lung adenocarcinoma by
fibro-blast growth factor 9 signaling through FGF receptor 3.
Cancer Res. 73:5730–5741. 2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Terai H, Soejima K, Yasuda H, et al:
Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism
of acquired resistance to gefitinib in NSCLC. Mol Cancer Res.
11:759–767. 2013. View Article : Google Scholar : PubMed/NCBI
|
27
|
Lefevre G, Babchia N, Calipel A, et al:
Activation of the FGF2/FGFR1 autocrine loop for cell proliferation
and survival in uveal melanoma cells. Invest Ophthalmol Vis Sci.
50:1047–1057. 2009. View Article : Google Scholar : PubMed/NCBI
|
28
|
Fillmore CM, Gupta PB, Rudnick JA, et al:
Estrogen expands breast cancer stem-like cells through paracrine
FGF/Tbx3 signaling. Proc Natl Acad Sci USA. 107:21737–21742. 2010.
View Article : Google Scholar : PubMed/NCBI
|